Fig. 5From: Atypical oral candidiasis in a psoriatic patient during targeted immunotherapy with an interleukin 17 inhibitor (secukinumab)Schematic demonstrating the overall hypothesis that the blocks interleukin (IL)-17A play key roles in oral candidiasis pathogenesisBack to article page